Proton

Proton Intelligence is a medical technology company developing a first-in-class continuous potassium monitoring (CKM™) platform designed to revolutionize the management of cardio-kidney-metabolic diseases. Its core technology is a wearable biosensor that provides real-time, on-demand data on potassium levels, a critical biomarker for patients with chronic kidney disease (CKD) and heart failure. By enabling proactive monitoring of electrolyte imbalances, the platform helps clinicians and patients prevent life-threatening complications such as cardiac arrhythmias and sudden cardiac death. Headquartered in Vancouver with R&D operations in Melbourne, the company is an alum of the SOSV IndieBio program and is currently advancing through clinical feasibility trials and human validation studies.